Evidence map›Paper›PMID 37066055›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2023

Monitoring Blood Supply in Germany: A Regulatory Perspective.

Sarah Anna Fiedler, Olaf Henseler, Marcus Hoffelner, Manfred Doll, Gabriele Hutschenreuter, Jochen Hoch, Franz Weinauer, Andreas Humpe, Markus Benedikt Funk, Anneliese Hilger

Open access · goldAbstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2024
    Article
  2. Article
  3. Patient Blood Management: We Still Have Work to Do.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
  4. How to Ensure Blood Supply and Blood Safety in the Future.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Sarah Anna FiedlerDivision Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany.
Olaf HenselerSection of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany.
Marcus HoffelnerDivision Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany.
Manfred DollSection of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany.
Gabriele HutschenreuterInstitute of Transfusion Medicine, University Hospital, Rheinisch-Westfälische Technische Hochschule Aachen, Aachen, Germany.
Jochen HochInstitute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany.
Franz WeinauerGerman RC Blood Services, Working Group of the GRC, Berlin, Germany.
Andreas HumpeDivision of Transfusion Medicine, Cell Therapeutics and Haemostaseology University Hospital, LMU Munich, Munich, Germany.
Markus Benedikt FunkDivision Safety of Medicinal Products and Medical Devices, Paul-Ehrlich-Institut, Langen, Germany.
Anneliese HilgerSection of Transfusion Medicine, Paul-Ehrlich-Institut, Langen, Germany.
Paul Ehrlich Institut · DEGerman Red Cross · DELudwig-Maximilians-Universität München · DERWTH Aachen University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objectives: A sufficient supply of safe, high-quality blood components for transfusion is essential to the healthcare system in Germany. The requirements for the current reporting system are laid down in the German Transfusion Act. The present work elaborates on the advantages and limitations of the current reporting system and investigates the feasibility of a pilot project that collects specific data on blood supply based on weekly reports. Materials and Methods: Selected data on blood collection and supply from 2009 to 2021 derived from the §21 German Transfusion Act database were examined. In addition, a pilot study over a period of 12 months was conducted on a voluntary basis. The number of red blood cell (RBC) concentrates was documented and stock availability was calculated weekly. Results: From 2009 to 2021, the annual number of RBC concentrates decreased from 4.68 to 3.43 million, the per capita distribution decreased from 58 to 41 RBC concentrates per 1,000 inhabitants. These figures did not change significantly during the COVID-19 pandemic. The data of the 1-year pilot project represented 77% of the released RBC concentrates in Germany. Percentage share of O RhD positive RBC concentrates fluctuated between 35% and 22% and for O RhD negative concentrates between 17% and 5%. The availability of O RhD positive RBC concentrate stocks varied between 2.1 and 7.6 days. Conclusion: The data presented shows a decrease in annual RBC concentrate sales over an 11-year period and no further change over the past 2 years. A weekly monitoring of blood components detects acute problems in RBC provision and supply. Close monitoring seems helpful but should be combined with a nationwide supply strategy.

Indexed as

Blood availabilityBlood supplyMonitoringRed blood cell concentrates

Identifiers

PMID37066055
PMCPMC10090968
OpenAlexW4317354981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.